MRM Health, a clinical-stage biopharmaceutical company developing therapeutics for immune-mediated diseases, which unlock the power of the microbiome to restore immune balance, today announced that MH002, the Company’s lead rationally designed Live Biotherapeutic Product (LBP) candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate ulcerative colitis (UC).
Mayo Clinic researchers have identified an immune-regulating molecule that may help explain why some patients with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, do not respond to commonly used therapies.
For patients with Crohn's disease or ulcerative colitis who have exhausted other treatment options, a new combination therapy is showing results that offer hope for one of medicine's most treatment-resistant populations, according to findings from two studies to be presented today at Digestive Disease Week® (DDW) 2026.
University of Houston biologists have contributed to a potential breakthrough in treating Crohn's disease by shifting the clinical focus from symptom management to addressing a primary underlying cause of the condition.
Discover how everyday dietary choices rapidly reshape your gut microbiome and, over time, influence inflammation, metabolism, and long-term disease risk.
Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of
our websites
and requested to be notified of additional information.
